Kiniksa Pharmaceuticals is a privately-held biotechnology company, focused on developing and delivering therapeutics to patients with devastating diseases and unmet medical needs. The company is developing a pipeline of programs across various stages of development. Every Second Counts!
The company has significant funding and a clear vision of building a global generational company.
Our first program, KPL-716, is a first-in-class, fully-human, monoclonal antibody which targets a single epitope. It inhibits two key cytokine pathways that will potentially allow us to address many key and differentiating aspects of numerous diseases involving fibrosis and autoinflammation. Kiniksa is also actively looking to acquire or in-license additional programs and technologies across all stages of development.